US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.48 against a street estimate of 0.41 — a beat of 17.1%.
Analysts rate Takeda Pharmaceutical Co Ltd ADR a strong buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $22.61.
| Fund | Stake |
|---|---|
| Capital Research Global Investors | 0.61% |
| FMR Inc | 0.23% |
| Morgan Stanley - Brokerage Accounts | 0.20% |
| Adage Capital Partners Gp LLC | 0.19% |
| The Goldman Sachs Group Inc | 0.18% |
| Brandes Investment Partners & Co | 0.14% |
| BlackRock Inc | 0.10% |
| Arrowstreet Capital Limited Partnership | 0.10% |
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.31 / share ex-date Mar 31, 2026 · pay Jul 6, 2026 | 2026-03-31 |
| Dividend | $0.32 / share ex-date Sep 30, 2025 · pay Dec 11, 2025 | 2025-09-30 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Takeda Pharmaceutical Co Ltd ADR — free to start.
Google PlayApp StoreData updated 2026-09-18.